FDA’s Plausible Mechanism Pathway: Accelerating Personalized Medicine

Developing therapeutics to treat rare and ultra rare diseases can be a daunting process that’s full of challenges. The FDA’s introduction of a plausible mechanism pathway outlines an approach to address some of these challenges with a goal to enable market entry for highly personalized therapies, particularly where traditional randomized trials are not feasible.¹ This approach focuses on conditions with well-defined genetic etiology and therapies that can directly target those abnormalities. Key criteria outlined as considerations in the new pathway include treatment of a disease with a known biological cause, development of a product that targets the underlying disease cause, reliance on natural disease history, and ability for measurable clinical improvement. Application of this pathway was illustrated through a case of DNA base editing in an infant with carbamoyl-phosphate synthetase 1 (CPS1) deficiency, where rapid regulatory action enabled a customized therapy under an expanded-access Investigational New Drug (IND) application process.²  However, unlike conventional regulatory models, the plausible mechanism pathway that has been outlined by FDA leadership would allow for single-patient data to inform product development, paving the way for platform-based approvals across multiple genetic mutations. 

Implications for Cell and Gene Therapy Developers

For companies in the cell and gene therapy space, the plausible mechanism pathway represents both opportunity and responsibility. While more guidance and details are needed to better understand how the pathway will be implemented, it promises faster paths to market for bespoke therapies, opportunities to build scalable platforms, and more robust post-marketing strategies to monitor safety and efficacy while collecting real-world evidence. Therefore, success will hinge on precision editing, manufacturing agility, and proactive engagement with regulators. As the FDA signals flexibility and partnership, firms that align scientific innovation with regulatory expectations will be best positioned to lead in this evolving landscape.